Radiopharm Theranostics Ltd

Research Radiopharm Theranostics Ltd (RAD) on Bullrun: market cap AUD 42.57M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRAD
• ExchangeAU
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyAUD
• Market capAUD 42.57M
• Financial periodFY2025
• RevenueAUD 3.63M
• Revenue growth1114.3%
• Net income-AUD 38.34M
• Free cash flow-AUD 36.65M
• Gross margin1.1%

Valuation Snapshot

latest market cap is AUD 42.57M.

About Radiopharm Theranostics Ltd

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic;

Frequently asked questions

What is Radiopharm Theranostics Ltd's market cap?

Radiopharm Theranostics Ltd's market capitalization is AUD 42.57M.

What does Radiopharm Theranostics Ltd do?

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.